Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

NCT03709706 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

34

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated for reasons pertaining to feasibility

Conditions

Neoplasms

Interventions

DRUG: Lete-cel
DRUG: Pembrolizumab

Sponsor

GlaxoSmithKline

Collaborators

[object Object]